Founded: June 17, 1918 (Taisho 7)
Introduced an internal carbon pricing system targeting capital expenditures
Acquired Japan Tissue Engineering Co., Ltd., a company developing regenerative medicine
Supported a statement calling for higher greenhouse gas reduction targets
Integrated overseas automotive composite materials business and launched it as Teijin Automotive Technologies, establishing a consistent supply system in Europe
Obtained Science Based Targets (SBT) certification
Supported JCI's statement urging climate change action
Company history 'People, Chemistry, and 100 Years' received the 'Excellent Company History Award'
Established a joint venture company (RePEaT Co., Ltd.) aimed at licensing polyester chemical recycling technology
Commenced production and sales of biobased polycarbonate resin
Established Teijin Regent Co., Ltd. to expand regenerative medicine CDMO business
Commenced production and sales of carbon fibers using environmentally friendly raw materials
Purpose image: Formulated the Teijin Group's purpose 'Pioneering solutions together for a healthy planet': Detailed information
Launch of heart and vascular repair patch 'Symphorium®'
Transfer of Infocom Co., Ltd., an IT services provider
TA Frontier Co., Ltd. has begun full-scale sales of the hybrid material "WarpknitFuse," which combines knitted and woven fabrics. The material blends vertical loop knitting with horizontal warp threads, achieving both flexibility and a beautiful silhouette. Three distinct types with different characteristics will be sold for spring/summer 2027 fashion and casual apparel.
Teijin Corporation recorded special severance pay of 7 billion yen during the second quarter of the fiscal year 2027 for the consolidated accounting period. This is part of the Next Career Support System (Early Retirement Incentive Program) based on the mid-term management plan announced on May 11, 2026. The special severance pay has already been incorporated into the full-year consolidated earnings forecast for fiscal year 2027, and it does not affect performance.
Teijin and Okumura Group jointly developed the "wood-hybrid acoustic panel" for wooden buildings. In a real-scale test, the panel’s ability to block impact noise on heavy floors improved by 22 dB (four ranks) in the 63 Hz band compared to before installation, demonstrating superior sound insulation performance over conventional dry double floors. Future efforts will focus on expanding the application scope and verifying performance in actual buildings, aiming to enhance performance and advance technology.
On September 25, 2026, Teijin Rejinet entered into an agreement to join the global alliance ACGMP, composed of CDMOs in the cell and gene therapy field. As a founding member, it aims to strengthen the global development and manufacturing support network, promote the practical application of therapeutic products, and contribute to the early delivery of innovative therapies.
On October 20, Teijin enhanced dialogue opportunities with shareholders and deepened their understanding of the Teijin Group by holding the first tour at Teijin Soleil's Gosenko Farm, 'Pore Pore Farm'. On that day, 24 shareholders selected by lottery participated. Teijin Soleil is a special subsidiary established with the purpose of creating workplaces for people with disabilities, and it has an agriculture division and an office support division.
On October 20, 2026, Teijin Co., Ltd. renewed its partnership agreement with the UK-based Paysafe Envision Formula E Team, which it has been supporting since 2020. This renewal further demonstrates its commitment to addressing social challenges such as climate change and the circular economy.
Eisai Pharma will transfer the manufacturing and sales approval of "Laxobron Oral Solution 0.75%" to Alphresa Pharma and transfer sales. The transfer is scheduled for January 2027, after which Alphresa Pharma will conduct sales activities and provide information to healthcare professionals. The purpose is to ensure continuous stable supply to patients.
Eisai Pharma has transferred the manufacturing and sales approval of the expectorant 'Mucosolvan' to Nihon Chemifa and is transferring sales. Both companies are proceeding with the necessary procedures, and the transfer is scheduled for January 1, 2027. After the transfer, Nihon Chemifa will coordinate to conduct sales and information provision activities independently.
Teijin Limited and Asahi Kasei Corporation integrated their operations and established TA Frontier Co., Ltd. The new company manufactures and sells chemicals, building materials, and related products, with capital of 2 billion yen. Teijin holds 80% of the shares and Asahi Kasei holds 20%.
Teijin Limited announced that Teijin Frontier Co., Ltd. and Asahi Kasei Advance Corporation completed their business integration on October 1, 2026. The integration aims to improve operational efficiency and strengthen competitiveness.